natgillin/translations-raw huggingface dataset:
A method of treating or ameliorating a syndrome, disorder or disease, in a subject in need thereof comprising administering to the subject an effective amount of a compound of claim 1 or composition or medicament thereof in a combination therapy with one or more anti- inflammatory agents, or immunosuppressive agents, wherein said syndrome, disorder or disease is selected from the group consisting of: rheumatoid arthritis, and psoriasis. 
Spoj prema zahtjevu 1 ili pripravak ili njegov lijek za upotrebu u kombiniranoj terapiji s jednim ili više protuupalnih sredstava, ili imunosupresivnim sredstvima, za liječenje ili ublažavanje sindroma, poremećaja ili bolesti koja je odabrana iz skupine koja sadrži: reumatoidni artritis, te psorijazu. farmaceutski prihvatljivog nosača.
The compound according to claim 4 or a pharmacologically acceptable salt thereof, or a solvate or hydrate thereof, wherein the term "optionally having substituent(s)" has the meaning defined in claim 1, and wherein R1 is a hydrogen atom, a hydroxy group, a C1 to C6 alkyl group, a C1 to C6 alkoxy group, a halo-C1 to C6 alkyl group, a hydroxy C1 to C6 alkyl group, a carboxy C1 to C6 alkyl group, a carbamoyl C1 to C6 alkyl group, a mono C1 to C6 alkylcarbamoyl C1 to C6 alkyl group, a di-C1 to C6 alkylcarbamoyl C1 to C6 alkyl group, an aminosulfonyl C1 to C6 alkyl group, an aromatic heterocyclic C1 to C3 alkyl group optionally having substituent(s), or a phenyl C1 to C3 alkyl group optionally having substituent(s); 
Spoj u skladu sa patentnim zahtjevom 4 ili njegova farmakološki prihvatljiva sol, ili njegov solvat ili hidrat, gdje izraz "po izboru ima supstituent(e)" ima značenje definirano u patentnom zahtjevu 1, i gdje R1 je atom vodika, hidroksi grupa, C1 do C6 alkil grupa, C1 do C6 alkoksi grupa, halo-C1 do C6 alkil grupa, hidroksi C1 do C6 alkil grupa, karboksi C1 do C6 alkil grupa, karbamoil C1 do C6 alkil grupa, mono C1 do C6 alkilkarbamoil C1 do C6 alkil grupa, di-C1 do C6 alkilkarbamoil C1 do C6 alkil grupa, aminosulfonil C1 do C6 alkil grupa, aromatična heterociklična C1 do C3 alkil grupa koja po izboru ima supstituent(e), ili fenil C1 do C3 alkil grupa koja po izboru ima supstituent(e);
The anti-inflammatory agents are usually employed in an amount from 0.1 to 5 wt.%. 
Protuupalni agensi obično se koriste u količini od 0,1 do 5 težinskih %.
iii) a polynucleotide encoding the peptide portion of soluble CD52 glycoprotein of part i) or the fusion protein of part ii); 
iii) polinukleotida koji kodira peptidni dio topljivog glikoproteina CD52 iz dijela i) ili fuzijski protein iz dijela ii);
The method as claimed in claim 1 wherein said monitoring of said disease comprises determining regression, course or onset of said disease in a sample from a patient who has said disease or is suspected of falling ill with said disease. 
Postupak prema bilo kojem od patentnih zahtjeva 6 do 9 naznačen time što navedeno praćenje navedene bolesti kancera sadrži određivanje regresije, toka ili početka navedene bolesti u uzorku od pacijenta koji ima navedenu bolest ili za koga se sumnja da se razboljeva od navedene bolesti.
The pharmaceutical composition for use according to claim 1 or 2, wherein the composition provides steady state plasma levels of 3a-hydroxy-3B-methoxymethyl-21-(1'-imidazolyl)-5a-pregnan-20-one in a range of from 50 ng/mL to 250 ng/mL. 
Farmaceutski sastav za uporabu prema patentnom zahtjevu 1, naznačen time, da sastav daje stacionarno stanje razine u plazmi 3a-hidroksi-3B-metoksimetil-21-(1'-imidazolil)-5a-pregnan-20-ona u području od 50 ng/ml do 250 ng/ml.
The key combination element 26 may apply the urging force against the lock combination element without help from any other force (such as from some spring) being applied to key combination element 26 . 
Element kombinacije ključa 26 može prenijeti silu na element kombinacije brave bez pomoći bilo koje druge sile (kao npr. od opruge) primjenjenje na element kombinacije ključa 26.
dispersing a second quantity of HPMC in said solution; and adding a second anti-solvent to said solution so as to crystallize said compound on the inside and on the surface of said HPMC and thereby form said formulation, wherein said second anti-solvent is a combination consisting essentially of acetone and isopropyl acetate (IPAC). The process of claim 1, further comprising the steps of filtering, washing and drying said formulation. 
Cc) - dispergiranje prve količine HPMC u navedenoj otopini; d) = dodavanje druge količine navedenog prvog protuotapala u navedenu otopinu; e) = dispergiranje druge količine HPMC u navedenoj otopini; i f) - dodavanje drugog protuotapala u navedenu otopinu kako bi se kristalizirao navedeni spoj s navedenim HPMC i tako dobila navedena formulacija, gdje je navedeno drugo protuotapalo kombinacija koja se uglavnom sastoji od acetona i izopropil-acetata (IPAC). 2. Postupak u skladu s patentnim zahtjevom 1, naznačen time što dodatno sadrži korake filtriranja, ispiranja i sušenja navedenog kristaliziranog spoja.
The optical device of claim 9 wherein at least two diffractive optical elements are provided in a photonic crystal. 
Optički uređaj u skladu s patentnim zahtjevom 12, naznačen time što se u fotonskom kristalu (19) nalaze najmanje dva difraktivna optička elementa.
The method of claim 1, wherein the paroxetine mesylate is in an amorphous form. 
3. - Paroksetin za upotrebu prema patentnom zahtjevu 1, naznačen time što je paroksetin u amorfnom obliku.
The processes for preparation can utilize racemates, enantiomers or diastereomers as starting materials. 
Kao početni materijali za proces pripreme mogu se koristiti racemati, enantiomeri ili dijastereomeri.
at least two thermoblocks (3, 4) respectively being in fluid connection with said at least one water reservoir (1, 2), 
- < najmanje dva termobloka (3, 4) koji su u odgovarajućem fluidnom kontaktu s, najmanje jednim, spremnikom za vodu (1, 2),
The present invention provides a process for the preparation of [1-hydroxy-2-(3-pyridinyl)ethylidene]bisphosphonic acid wherein aqueous solution of 3-pyridyl acetic acid hydrochloride is added dropwise to phosphorus trichloride at a temperature of 0-5° C. in the initial stage of the process. 
Ovaj izum pribavlja postupak za pripravu [1-hidroksi-2-(3-piridinil)etiliden] bisfosfonske kiseline u kojem se vodena otopina hidroklorida 3-piridinil octene kiseline doda kap po kap fosfor-trikloridu pri temperaturi od 0-5 *C u početnom stadiju postupka.
A process for producing a pharmaceutical composition according to embodiment 32, said process comprising admixing the bacterial species Roseburia hominis with a pharmaceutically acceptable excipient, carrier or diluent. 
Postupak za proizvodnju farmaceutskog sastava prema zahtjevu 2, naznačen time što sadrži miješanje bakterijske vrste Roseburia hominis sa farmaceutski prihvatljivim ekscipijensom, nosačem ili diluentom.
A thirteenth example concerns the preparation of "butterscotch" caramel, in which the same ingredients as for the twelfth example are used, but wherein the water is replaced by 100 g cream with a fat content of 40 %. 
U trinaestom primjeru opisuje se priprava «butterscotch» karamela, za koji se koriste jednaki sastojci kao i za pripravu karamela iz dvanaestog primjera, no voda je zamijenjena sa 100 g slatkog vrhnja s 40 % mliječne masti.
A method according to claim 1, wherein said atmospheric pressure plasma is applied using single jet electrode with a distance of at least 2 mm from said synthetic polymer material. 
Metoda u skladu sa patentnim zahtjevom 1, gdje navedena plazma na atmosferskom pritisku je primijenjena korištenjem elektrode sa pojedinačnim mlazom sa udaljenosti od najmanje 3 mm od navedenog poliolefinskog materijala.
introduce the loading form into an inner space of the loading members, placing the portion of knitted article wrapped outside the loading form in front of the fabric strip wrapped around the loading members, so that the fabric strip surrounds outside the end portion of the knitted article and lies concentrically with respect to the latter; 
– umetanja kalupa za punjenje (11) u unutarnji prostor (32) naprava za punjenje (31), stavljanja dijela pletenog artikla na takav način da se omota izvan kalupa za punjenje ispred trake od tkanine omotane oko naprava za punjenje, na takav način da traka od tkanine okružuje s vanjske strane krajnjeg dijela pletenog artikla i leži koncentrično u odnosu na potonji;
TABLE 1 Test of vasorelaxation 
Tablica 1- Ispitivanje vazorelaksacije
The process according to Claim 1 or Claim 2, wherein the introduction of the ozone into the emulsion is for a treatment period of from 1 hour to 24 hours. 
Postupak prema zahijevu 1 ili zahtjevu 2, naznačen time da se uvođenje ozona u emulziju provodi tijekom razdoblja obrade u trajanju od 1 sata do 24 sata.
The process according to claim 8 wherein said alkaline metal alkoxide is selected from the group consisting of lithium methoxide, lithium ethoxide, lithium isopropoxide, lithium tert-butoxide, sodium methoxide, sodium ethoxide, sodium isopropoxide, sodium tert-butoxide, potassium methoxide, potassium ethoxide, potassium isopropoxide, potassium tert-butoxide, cesium methoxide, cesium ethoxide, cesium isopropoxide and cesium tert-butoxide. 
Postupak prema patentnom zahtjevu 8 gdje se navedeni alkalni metalni alkoksid bira iz skupine koja se sastoji od litijevog metoksida, litijevog etokisda, litijevog izopropoksida, litijevog terc-butoksida, natrijevog metoksida, natrijevog etoksida, natrijevog izopropoksida, natrijevog terc-butoksida, kalijevog metoksida, kalijevog etoksida, kalijevog izopropoksida, kalijevog terc-butoksida, cezijevog metoksida, cezijevog etoksida, cezijevog izopropoksida i cezijevog terc-butoksida.
A compound, or a pharmaceutically acceptable salt or hydrate thereof, or pharmaceutical composition of any of claims 1 to 9 or 11 to 25 for use in a method of treating a cancer characterized by the presence of an IDH1 mutation, wherein the IDH1 mutation results in a new ability of the enzyme to catalyze the NADPH-dependent reduction of a-ketoglutarate to R (-)-2-hydroxyglutarate in a patient. 
Spoj, ili njegova farmaceutski prihvatljiva sol ili hidrat, ili farmaceutska kompozicija prema bilo kojem od patentnih zahtjeva 1 do 9 ili 11 do 25 za upotrebu u postupku za liječenje karcinoma naznačeno prisustvom IDH1 mutacije, pri čemu IDH1 mutacija rezultira u novoj sposobnosti enzima da katalizira NADPH-zavisnu redukciju a-ketoglutarata u R(-)-2-hidroksiglutarat u pacijentu.
wherein the output level of the audio signal is determined by using an equation shown below: 
Postupak prema Zahtjevu 5, gdje se izlazni nivo audio signala određuje korištenjem jednadžbe prikazane ispod:
detecting (202) the application of said candidate signal (Sc) to the binary input (2); 
- | detektiranju (202) primjene navedenog kandidatnog signala (S.) na binarni ulaz (2);
Example 1.1: Ouantification of the amount of insoluble particles 
Datum podnošenja europske prijave patenta:
The unit dose of any one of claims 1-12, which upon subcutaneous injection causes a reduced daily five-minute Local Injection Site Reaction (LISR) score upon subcutaneous injection relative to the daily 5-minute LISR score associated with subcutaneous injection of 1.0ml of an aqueous pharmaceutical solution of 20mg glatiramer acetate and 40mg mannitol. 
Jedinična doza prema bilo kojem od patentnih zahtjeva 1-12, naznačena time, da nakon supkutane injekcije uzrokuje smanjenu dnevnu vrijednost lokalne reakcije na mjestu uboda (LISR) nakon 5 minuta, u odnosu na dnevnu vrijednost lokalne reakcije na mjestu uboda nakon 5 minuta, povezane sa supkutanom injekcijom od 1,0 ml vodene farmaceutske otopine od 20 mg glatiramer acetata 1 40 mg manitola.
A process for preparing a herbicidal composition as defined in claim 8, which comprises mixing water with the components a) and b) of the herbicidal mixture with or without further additives. 
Postupak za pripremu herbicidne smjese prema patentnom zahtjevu 8, koji sadrži miješanje vode sa komponentama a) 1b) herbicidne smjese sa ili bez dodatnih aditiva.
providing a discharge which is situated in the centre with respect to the annular line, 
- < izvedba ispusta (28) koji se nalazi u središtu s obzirom na pomoćnu injekcijsku liniju (25),
The invention also relates to a drink dispenser and a container for use in such a dispenser. 
Izum se također odnosi i na raspršivač pića i spremnik za upotrebu u takvom razdjelniku.
A co-suspension according to statement 17, wherein the suspending particles are included in the suspension medium at a concentration selected from between about 1 mg/mL to about 15 mg/mL, about 3 mg/mL to about 10 mg/mL, about 1.5 mg/mL to about 10 mg/mL. 
Ko-suspenzija u skladu s patentnim zahtjevom 3, naznačena time što su suspendirajuće čestice uključene u medij za suspenzije u koncentraciji koja se bira između od 1 mg/ml do 15 mg/ml, 3 mg/ml do 10 mg/ml, te 1,5 mg/ml do 10 mg/ml.
The aqueous agrochemical suspension formulation of [6], wherein an amount of 2-(2,6-difluorophenyl)-4-[4-(1,1-dimethylethyl)-2-ethoxyphenyl]-4,5-dihydrooxazole is within a range of 0.1 to 50 weight %, an amount of the at least one kind of alcohol selected from the group consisting of ethylene glycol, propylene glycol and glycerin is within a range of 0.2 to 10 weight % and an amount of the inorganic thickener is within a range of 0.1 to 5 weight % and an amount of the dispersant is within a range of 1 to 15 weight %, as opposed to the total amount of the formulation. 
Vodena agrokemijska suspenzija u skladu sa patentnim zahtjevom 1, gdje suspenzija je formulacija 1 količina 2- (2,6-difluorofenil)-4-[4-(1,1-dimetiletil)-2-etoksifeml]-4,5-dihidrooksazola je u okviru opsega od 0.1 do 50 masenih %, količina barem jedne vrste alkohola odabrane iz grupe koja se sastoji od etilen glikola, propilen glikola i glicerina je u okviru opsega od 0.2 do 10 masenih % i količina neorganskog sredstva za zgušnjavanje je u okviru opsega od 0.1 do 5 masenih % 1 količina dispergirajućeg sredstva je u okviru opsega od 1 do 15 masenih %, za razliku od ukupne količine formulacije.
1 and 4, the filter module 1 and/or its filter layers 4 are not located alongside the entire cross-section of the generated air flow 52 and/or the entire projected cross-section of the ventilator 2, which is defined by the circulating rotor blades 15 but leaves a bypass channel 50, through which the air flow 52 may bypass the filter layers 4 freely and without being filtered. 
Filtarski modul sukladno jednom od prethodnih zahtjeva, pri čemu slojevi filtara (4) uključuju najmanje jedan dio bez okvira, koji se nalazi bočno od slojeva filtara (4) i kroz koji zrak može slobodno protjecati, pri čemu je taj dio dizajniran tako da na njega ne utječu sustavi za provođenje 1 opstrukciju zraka poput pregrada 1li slično.
Substitutions Substitutions Ala (A) 
(a) MMAE koja ima strukturu:
The method of purifying the pegylated AvPAL variant may further comprise freezing and thawing the eluate from the HIC column comprising the AvPAL variant, wherein one or more polyols or sugars, such as about 2.5%, 5%, 7.5%, 10%, 12.5% or 15% glycerol, sucrose, glucose, trehalose, mannitol or sorbitol, or the like is added to the HIC column eluate prior to freezing. 
Postupak u skladu s patentnim zahtjevom 2 ili 3, naznačen time što se dodatno sastoji u smrzavanju i odmrzavanju eluata iz HIC stupca koji sadrži varijantu AvPAL dobivenu u koraku (e), gdje se jedan ili više poliola ili šećera koje se bira iz skupine koju čine glicerol, saharoza, glukoza, trehaloza, manitol i sorbitol dodaje eluatu iz HIC stupca prije smrzavanja.
blocks or inhibits artemin-dependent activation of RET with an IC50 ranging from about 200 pM to about 50 nM; 
blokira ili inhibira aktivaciju RET-a ovisnu o arteminu, uz vrijednost IC50 u rasponu od 200 pM do oko 50 nM;
The method according to claim 1, wherein the medicament is a cream. The method according to claim 15, wherein the medicament is a hydrophilic cream. The method according to claim 1, wherein the medicament comprises about 1% to about 10% by weight of the composition of allopurinol or a pharmaceutically acceptable salt thereof. 
Lijek za uporabu prema bilo kojem od patentnih zahtjeva 1-4, naznačen time da je lijek krema, preporučeno hidrofilna krema. Lijek za uporabu prema patentnim zahtjevima 1 do 5, naznačen time da sadrži od 1-10% masenog udjela alopurinola ili njegove farmaceutski prihvatljive soli, preporučeno od 1% do 8%, te još bolje od 2 do 5% masenog udjela.
The present invention furthermore relates to a method of treating a subject suffering from an immunoregulatory abnormality, comprising administering to said subject a compound of formula (I), and related formulae in an amount that is effective for treating said immunoregulatory abnormality. The present invention preferably relates to a method wherein the immunoregulatory abnormality is an autoimmune or chronic inflammatory disease selected from the group consisting of: allergic diseases, amyotrophic lateral sclerosis (ALS), systemic lupus erythematosus, chronic rheumatoid arthritis, type I diabetes mellitus, inflammatory bowel disease, biliary cirrhosis, uveitis, multiple sclerosis, Crohn's disease, ulcerative colitis, bullous pemphigoid, sarcoidosis, psoriasis, autoimmune myositis, Wegener's granulomatosis, ichthyosis, Graves ophthalmopathy and asthma. 
Spoj prema zahtjevu 7 naznačen time da je autoimuna bolest odabrana iz skupine koju čine astma, reumatoidni artritis, akutni diseminirani encefalomijelitis (ADEM), Addisonova bolest, alopecija areata, ankilozirajući spondilitis, sindrom antifosfolipidnih protutijela (APS), autoimuna hemolitička anemija, autoimuni hepatitis, autoimuna bolest unutarnjeg uha, bulozni pemfigoid, Behcetova bolest, celijakija, anti-transglutaminaza, Chagasova bolest, kronična opstruktivna plućna bolest, Crohnova bolest, dermatomiozitis, šećerna bolest tip 1, endometrioza, Goodpastureov sindrom, Gravesova bolest, Guillain-Barrć sindrom (GBS), Hashimotova bolest, Hidradenitis suppurativa, Kawasakijeva bolest, IgA nefropatija, idiopatska trombocitopenična purpura, intersticijski cistitis, eritemski lupus, miješana bolest vezivnog tkiva, morfea, multipla skleroza (MS), miastenija
A compound of Formula III: or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, wherein: 
Spoj Formule I: [image] ili njegova farmaceutski prihvatljiva sol, solvat ili stereoizomer, naznačen time, da:
In some embodiments, the particle size of the filler(s) is/are in the range of 0.2-20 um with some very fine particles of about 0.04 um. 
U nekim cjelinama veličina čestice punila je u rasponu od 0.2-20 um s nešto vrlo finih čestica od oko 0.04 um.
An intermediate compound for preparing a compound of Claim 1 or a pharmaceutically acceptable salt thereof, the intermediate compound having formula 3a: wherein Rx and Ry are independently selected from C1-4 alkyl, phenyl, and -C1-4 alkyl-(phenyl); 
Intermedijarni spoj za pripravu spoja iz patentnog zahtjeva 1, naznačen time, da intermedijarni spoj ima formulu: g & I pri čemu R*iR* su neovisno odabrani od C,4 alkila, fenila i -C,.4 alkil-(fenil);
hyper-oxygenating tumors to improve the therapeutic effect of radiation therapy or chemotherapy. 
(V) hiperoksigenacija tumora radi poboljšanja terapeutskog učinka efekta terapije zračenjem ili kemoterapije.
in the presence of a suitable reducing agent; and treating the resulting compound of formula (VI): 
ša Će u prisutnosti prikladnog ređukcijskog agensa; ili (b) obradu spoja formule (VI) oz g"
The process according to claim 1, further characterized in that fraction A is present in an amount ranging from at least 40% to at most 50% by weight based on the total weight of the virgin Ziegler-Natta catalyzed polyethylene resin. 
Postupak prema bilo kojem zahtjevu od 1 do 10 dalje karakteriziran time da frakcija A je prisutna u težinskom udjelu između najmanje 40% do najviše 50% u odnosu na ukupnu težinu neobrađene polietilenske smole; poželjno u rasponu od najmanje 40% do najviše 45% težinskog udjela u odnosu na ukupnu težinu neobrađene polietilenske smole.
Method according to claim 7, wherein the polyphosphoric acids or their salts are; 
Postupak prema zahtjevu 5, pri čemu su polifosforne kiseline ili njihove soli:
The infrastructure according to claim 1, in which dissipation of the wave motion which breaks against the openings of the vertical walls occurs by front diffraction and side reflection of a wave, thus obtaining a gradual attenuation. 
Infrastruktura u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačena time što rasipanje gibanja valova koje se probija prema otvorima ili prozorima (17) okomitih zidova (12, 13 i 14) nastaje prednjom difrakcijom i bočnim odrazom vala, čime se dobiva postupno prigušenje.
The apparatus of claim 1, wherein, when the intra prediction mode is a planar mode, the intra prediction unit (150) generates the prediction block using a corner reference pixel, a left reference pixel and an upper reference pixel. The apparatus of claim 1, wherein the filter is not applied to the horizontal mode and the vertical mode. 
Uređaj iz zahtjeva 1, pri čemu, kada je filter primjenjen na intrapredikcijski režim sa smjerom od 45° u odnosu na horizontalni režim i kada nije primjenjen na horizintalni režim i vertikalni režim.
breaking the adduct of quinine and Compound (C-1) by treating the adduct with HCl to form Compound (C-1) or a pharmaceutically acceptable salt thereof; 
rastavljanju adukta kinina sa Spojem (C-1) obradom adukta s HCl kako bi se dobilo Spoj (C-1), ili njegovu farmaceutski prihvatljivu sol;
For example, the cancer may be selected from the group consisting of: prostate cancer; breast cancer; colorectal cancer; pancreatic cancer; ovarian cancer; lung cancer; cervical cancer; rhabdomyosarcoma; neuroblastoma; multiple myeloma; leukemia, acute lymphoblastic leukemia, melanoma, bladder and glioblastoma. In one embodiment, the cancer is associated with CD40+ tumour cells. 
Protutijelo ili fragment za vezanje antigena ili molekula nukleinske kiseline ili vektor ili stanica domaćina ili farmaceutski pripravak za upotrebu prema zahtjevu 12, naznačen time da se rak bira iz skupine koja sadrži: rak prostate; rak dojke; rak debelog crijeva; rak gušterače; rak jajnika; rak pluća; rak grlića maternice; rabdomiosarkom; neuroblastom; multipli mijelom; leukemiju, akutnu limfoblastnu leukemiju, melanom, rak mokraćnog mjehura i glioblastom.
According to one embodiment, the calcium carbonate-containing material provided in step a) is selected from natural calcium carbonate sources and preferably is selected from the group consisting of marble, limestone, chalk, dolomite, and mixtures thereof. 
Postupak prema zahtjevu 1, naznačen time da je materijal koji sadrži kalcijev karbonat osiguran u koraku a) odabran iz prirodnih izvora kalcijevog karbonata i poželjno je odabran iz skupine koja se sastoji od mramora, vapnenca, krede, dolomita, i njihovih smjesa.
tumor diseases, which coincide with inflammatory and/or proliferative processes, 
(xiv) tumorskih bolesti, koje se poklapaju s upalnim i/ili proliferativnim procesima,
In another aspect the present invention provides the use of a compound of formula (I) or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament, for the treatment or prophylaxis of neurodegenerative disorders, demyelinating disease, cardio- and cerebrovascular atherosclerotic disorders, peripheral artery disease, rheumatoid arthritis, pulmonary diseases such as COPD, asthma or pain. 
Upotreba spoja formule (T) kako je definirano u bilo kojem zahtjevu 1 do 10, ili njegove farmaceutski prihvatljive soli, naznačena time, da se navedeni spoj upotrebljava za proizvodnju lijeka za liječenje ili profilaksu neurodegenerativnih poremećaja, bolesti demijelinacije, kardio- i cerebrovaskularnih ateroskleroznih poremećaja, bolesti perifernih arterija, reumatoidnog artritisa, plućnih bolesti poput COPD, astme ili boli.
is a covalent bond or together with the —OC(═O)— group forms a self-immolative linker; and wherein the linker L is attached to the pyrrolobenzodiazepine (PBD) at the position of the asterisk (*). 
L? je kovalentna veza ili zajedno s -OC(=0)-skupinom, tvori samožrtvujuću poveznicu; i pri čemu je poveznica L priključena na pirolobenzodiazepin (PBD) na poziciji zvjezdice (*);